Abstract
Many variants of the DR3/LARD death receptor mRNA are derived during alternative splicing. Different DR3/LARD mRNAs encode the membrane and soluble forms of the receptor, which perform different functions. The frequency of the spliced mRNA variants of DR3/LARD was assessed by RT-PCR in patients with colorectal cancer and in cancer cell lines. Four forms of the DR3/LARD death receptor mRNA were detected with different frequencies in the studied samples. Two of them encoded the membrane molecules (LARD 1a mRNA and DR3β mRNA) and two other forms expressed the soluble forms of the receptor (LARD 3 mRNA and soluble DR3β mRNA). In the blood of healthy volunteers, 11 variants (spectra) of DR3/LARD mRNA forms were identified, and the full spectrum that included all four variants of DR3/LARD mRNA dominated. In blood and tumor center samples from patients with colon cancer, six spectra of DR3/LARD mRNA were found. The diversity of the DR3/LARD mRNA spectra was decreased in colon cancer patients due to the reduced frequency of soluble DR3β mRNA. In samples of tumor centers, the spectrum with the absence of only mRNA of the soluble DR3β form dominated. In the blood of patients, two spectra prevailed, i.e., the full spectrum and LARD 1a mRNA and LARD 3 mRNA. Only these two spectra of DR3/LARD mRNA were also found in cancer cell lines. Distinctions in the frequency of DR3/LARD mRNA spectra in healthy volunteers and patients with colorectal cancer can define the different susceptibility of immunocompetent and tumor cells to apoptosis signals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CRC:
-
colorectal cancer
References
Ozören N., El-Deiry W.S. 2003. Cell surface death receptor signaling in normal and cancer cell. Semin. Cancer Biol. 13, 4615–4619.
Borysenko C.W., Furey W.F., Blair H.C. 2005. Comparative modeling of TNFRSF25 (DR3) predicts receptor destabilization by a mutation linked to rheumatoid arthritis. Biochem. Biophys. Res. Commun. 328, 794–799.
Gout S., Morin C., Houle F., Huot J. 2006. Death receptor-3, a new E-selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MARK activation. Cancer Res. 66, 9117–9124.
Utkin O.V., Novikov V.V. 2007. Regulation of apoptosis by alternative pre-mRNA splicing. Ross. Bioterapevt. Zh. 2, 13–20.
Warzocha K., Ribeiro P., Charlot C., et al. 1998. A new death receptor 3 isoform: Expression in human lymphoid cell lines and non-Hodgkin’s lymphomas. Biochem. Biophys. Res. Commun. 242, 376–379.
Screaton G.R., Xu X.-N., Olsen A.L. et al. 1997. LARD: A new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc. Natl. Acad. Sci. U. S. A. 94, 4615–4619.
Utkin O.V., Novikov V.V. 2012. Death receptors in modulation of apoptosis. Usp. Sovrem. Biol. 4, 381–390.
Ananyev V.S., Kulushev V.M., Korotkova O.V., Zalit N.Yu., Vardapetian E.V.. 2006. Immunological correction of patients with colorectal cancer after treatment with Galavit, Ross. Bioterapevt. Zh. 2, 81–84.
Chomszynskii P., Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyonatephenol-chloroform extraction. Anal. Biochem. 162, 156–159.
Sambrook J., Fritsch E.F., Maniatis T. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Lab. Press.
Park M.H., Song M.J., Cho M.-C., et al. 2011. Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology. 135, 63–72.
Wang E.C., Thern A., Denzel A., et al. 2001. DR3 regulates negative selection during thymocyte development. Mol. Cell. Biol. 21, 3451–3461.
Borysenko C.W., A-Palacios V.N., Griswold R.D., et al. 2006. Death receptor-3 mediates apoptosis in human osteoblasts under narrowly regulated conditions. J. Cell. Physiol. 209, 1021–1028.
Pappu B.P., Borodovsky A., Zheng T.S., et al. 2008. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J. Exp. Med. 205, 1049–1062.
Papoff G., Cascino I., Eramo A., et al. 1996. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J. Immunol. 156, 4622–4630.
Sakharnov N.A., Novikov D.V., Alyasova A.V., Novikov V.V. 2010. Fas mRNA alternative splicing in colorectal cancer tumor cells. Vestn. Nizhegorod. Gos. Univ. im. N.I. Lobachevskogo, Ser. Biol., 2, 580–584.
Bellot G.L., Tan W.H., Tay L.L., et al. 2012. Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients. J. Cancer Res. Clin. Oncol. 138, 463–482.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © O.V. Utkin, V.D. Starikova, A.D. Perenkov, O.S. Yanchenko, A.Yu. Baryshnikov, V.V. Novikov, 2013, published in Molekulyarnaya Biologiya, 2013, Vol. 47, No. 5, pp. 828–834.
Rights and permissions
About this article
Cite this article
Utkin, O.V., Starikova, V.D., Perenkov, A.D. et al. DR3/LARD spliced mRNA variants’ frequency in colorectal cancer. Mol Biol 47, 721–726 (2013). https://doi.org/10.1134/S0026893313050208
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893313050208